Valuation: Alaunos Therapeutics, Inc.

Market Cap 4.82M 4.17M 3.89M 3.57M 6.72M 459M 6.82M 45.68M 17.93M 230M 18.1M 17.7M 760M P/E 2024
-0.65x
P/E 2025 -1.47x
Enterprise Value 3.44M 2.97M 2.77M 2.55M 4.79M 327M 4.86M 32.56M 12.78M 164M 12.9M 12.62M 542M EV / Sales 2024
195,938,500x
EV / Sales 2025 1,164,761,400x
Free-Float
84.27%
Yield 2024 *
-
Yield 2025 -
1 week+5.85%
Current month+5.85%
1 month-3.86%
3 months-22.87%
6 months-24.33%
Current year-38.39%
1 week 1.85
Extreme 1.8501
2.02
1 month 1.81
Extreme 1.81
2.19
Current year 1.81
Extreme 1.81
4.04
1 year 1.67
Extreme 1.67
4.59
3 years 1.31
Extreme 1.3137
63.73
5 years 1.31
Extreme 1.3137
601.5
10 years 1.31
Extreme 1.3137
1,182
Manager TitleAgeSince
Chief Executive Officer 63 02/07/2025
Director of Finance/CFO 41 22/02/2025
Director TitleAgeSince
Director/Board Member 57 16/12/2020
Chairman 63 22/09/2023
Director/Board Member 72 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
23/7/26 Free

Director

8,138 0.3332%
23/7/26 Free

Chief Executive Officer

4,568 0.1870%
23/7/26 Free

Director

8,463 0.3465%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+5.85%-19.43%-96.87% 4.82M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.46%+11.10%+46.65%+177.17% 26.36B
Weighted average by Cap. +4.36%+13.10%+50.69%+168.47%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.95 0.01 0.09 0.04 0.48 0.04 0.04 1.58 0 0 0 0 0.01 0.48 0.01 0.05 0.02 0.24 0.02 0.02 0.79
Net income -4.68M -4.05M -3.78M -3.47M -6.52M -445M -6.62M -44.34M -17.4M -223M -17.57M -17.19M -738M -4.18M -3.61M -3.37M -3.09M -5.82M -397M -5.91M -39.58M -15.53M -199M -15.68M -15.34M -659M
Net Debt -1.09M -944K -881K -808K -1.52M -104M -1.54M -10.34M -4.06M -52.04M -4.1M -4.01M -172M -1.38M -1.2M -1.12M -1.03M -1.93M -132M -1.96M -13.13M -5.15M -66.07M -5.2M -5.09M -218M
Logo Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Employees
1
Date Price Change Volume
07/08/26 USD 1.990 0.00% 6,060
06/08/26 USD 1.990 -1.49% 5,042
05/08/26 USD 2.020 +6.32% 11,770
04/08/26 USD 1.900 -0.26% 11,006
03/08/26 USD 1.905 +1.33% 4,862

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRT Stock